The present invention generally relates to the microbiological industry, and specifically to the production of L-serine using genetically modified bacteria. The present invention provides genetically modified microorganisms, such as bacteria, wherein the expression of genes encoding for enzymes involved in the degradation of L-serine is attenuated, such as by inactivation, which makes them particularly suitable for the production of L-serine at higher yield. The present invention also provides means by which the microorganism, and more particularly a bacterium, can be made tolerant towards higher concentrations of serine. The present invention also provides methods for the production of L-serine or L-serine derivative using such genetically modified microorganisms.

The disclosure relates to a nucleic acid molecule isolated from a Papaver somniferum cultivar that produces the opiate alkaloid noscapine which comprises 10 genes involved in the biosynthesis of opiate alkaloids.

The present application relates to a microorganism in which an activity of erythronate-4-phosphate dehydrogenase is weakened; a method for producing O-phosphoserine, cysteine, or cysteine derivatives using the microorganism; a composition for producing O-phosphoserine comprising the microorganism; and the use of the microorganism in the production of O-phosphoserine, cysteine, and cysteine derivatives.

A method for converting a carbon source into serine includes: synthesizing a DNA sequence; implanting the DNA sequence into a plasmid, so that the plasmid includes gene sequences of SEQ ID NO: 1, SEQ ID NO: 2, and SEQ ID NO: 3; implanting the plasmid into cyanobacteria through an electroporation treatment, so as to obtain modified cyanobacteria; and providing the carbon source to the modified cyanobacteria, so that the modified cyanobacteria convert the carbon source into the serine.

The present invention generally relates to novel compositions and methods for regenerating damaged cardiac tissue. In some embodiments, the invention comprises activators of phosphor-serine aminotransferase (PSAT1) and methods of use thereof for the treatment of damaged cardiac tissue following myocardial infarction.

A method for converting a carbon source into ethylene glycol includes: providing a plasmid, in which the plasmid includes gene sequences of SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, and SEQ ID NO: 6; implanting the plasmid into cyanobacteria through an electroporation treatment, so that modified cyanobacteria are obtained; and providing the carbon source to the modified cyanobacteria, so that the modified cyanobacteria convert the carbon source into the ethylene glycol.

Disclosed herein are polynucleotides comprising sequences encoding coenzyme M synthase (ComF) linked to a heterologous regulatory element and methods of using the same. The polynucleotides may comprise synthetic operons comprising additional sequences encoding enzymes, e.g., a taurine-pyruvate aminotransferase, a sulfoacetaldehyde acetyl transferase, or a sulfopyruvate decarboxylase. Also disclosed herein are recombinant prokaryotic cells, e.g., recombinant bacterial, e.g., E. coli, or archaeal cells, e.g., Methanosarcina acetivorans with improved tolerance to oxidative stress.

An O-phosphoserine (OPS) export protein variant with increased O-phosphoserine exporting activity, and a method for producing O-phosphoserine, cysteine, and cysteine derivatives using the same. Also provided herein are O-phosphoserine-producing microorganisms, a polynucleotide encoding the O-phosphoserine export protein variant, and a vector containing the polynucleotide encoding the O-phosphoserine export protein variant.

Provided are a microorganism producing an L-amino acid or a precursor thereof, and a method of producing an L-amino acid or a precursor thereof using the microorganism.

The present disclosure provides a method for producing a methyl compound using glycine, serine, or an organic raw material.